Skip to content

Knee Nerve Cryoneurolysis and Impact on Pain After Prosthetic Surgery

Cryoneurolysis of the Saphenous Nerve or Geniculate Nerves: Impact on Postoperative Pain and Rehabilitation in Prosthetic Knee Surgery

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05059535
Acronym
Cryogenou
Enrollment
52
Registered
2021-09-28
Start date
2022-01-12
Completion date
2025-03-10
Last updated
2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Injuries

Brief summary

Interventional, comparative, randomized, controlled study versus standard treatment, in 3 parallel groups, monocentric, aiming to demonstrate the superiority of preoperative cryoneurolysis versus no procedure, in patients operated on for knee arthroplasty and receiving standard analgesia.

Interventions

DRUGstandard pain relievers

Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice

Sponsors

Euraxi Pharma
CollaboratorINDUSTRY
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years and ≤ 80 years; * Patient to undergo prosthetic knee surgery; * Patient in good health (ASA score 1 to 3); * Patient able to understand the information related to the study, read the information leaflet and agree to sign the consent form.

Exclusion criteria

* Known intolerance to any of the products administered during surgery or cryoneurolysis; * Patient with an electric implant; * Patient with a contraindication to cryoanalgesia (coagulation disorders, infections, nerve damage); * Drug addict patient; * Intervention on septic bone; * Chronic renal failure (creatinine clearance \<30 mL / min); * History of cryoglobulinemia, cold urticaria or Raynaud's syndrome; * Pregnant or breastfeeding woman; * Patient under guardianship or curatorship, or under a regime of deprivation of liberty; * Patient participating in another clinical trial, or in a period of exclusion from another clinical trial; * Patient not beneficiary of a social security scheme.

Design outcomes

Primary

MeasureTime frameDescription
90 ° flexion pain 2 days after the arthroscopy2 daysEvaluation of the knee pain at 90° flexion with a visual analogic scale of 100 mm

Secondary

MeasureTime frameDescription
90 ° flexion pain 7 days after the arthroscopy7 daysEvaluation of the knee pain at 90° flexion with a visual analogic scale of 100 mm
90 ° flexion pain 30 days after the arthroscopy30 daysEvaluation of the knee pain at 90° flexion with a visual analogic scale of 100 mm
90 ° flexion pain 90 days after the arthroscopy90 daysEvaluation of the knee pain at 90° flexion with a visual analogic scale of 100 mm
pain at rest at Day 11 dayKnee pain after intervention with a visual analogic scale of 100 mm
90 ° flexion pain 1 day after the arthroscopy1 dayEvaluation of the knee pain at 90° flexion with a visual analogic scale of 100 mm
pain at rest at Day 77 daysKnee pain after intervention with a visual analogic scale of 100 mm
pain at rest at Day 3030 daysKnee pain after intervention with a visual analogic scale of 100 mm
pain at rest at Day 9090 daysKnee pain after intervention with a visual analogic scale of 100 mm
pain at rest at Day 22 daysKnee pain after intervention with a visual analogic scale of 100 mm

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026